Ask AI
Kami Maddocks

Kami Maddocks, MD

Professor – Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Explore Activities by Kami Maddocks

Title
Format
Credit Type
Credits
Optimizing Outcomes for Relapsed/Refractory CLL/SLL and MCL

Content Format:

Slideset

Credit Type:

--

Credits:

--
Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams

Content Format:

Video

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.00
Current Advances in Relapsed/Refractory MCL: Expert Guidance for Community Hematology Care Teams

Content Format:

Slideset

Credit Type:

--

Credits:

--
Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Uma perspectiva global sobre os dados emergentes da terapia com inibidor de BTK para LLC e LCM recidivantes/refratários em 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Einblicke in neue Daten zu BTK-Inhibitoren bei CLL und MCL der Jahresversammlung der SOHO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Approfondimenti sui nuovi dati relativi agli inibitori di BTK per il trattamento della leucemia linfatica cronica (CLL) e del linfoma mantellare (MCL) come emersi dalla Conferenza annuale della SOHO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Conclusiones sobre los nuevos datos relativos a los inhibidores de la TQB para LLC y LCM de la Junta Anual de SOHO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Insights on New Data With BTK Inhibitors for CLL and MCL From the SOHO 2022 Annual Meeting

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Aperçu des nouvelles données sur les inhibiteurs BTK pour le traitement de la LLC et du LCM à l’occasion de la réunion annuelle de la SOHO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Insights sobre novos dados com inibidores de BTK para LLC e LCM da Reunião Anual da SOHO 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--